Suppr超能文献

台湾乳腺癌患者中HER-2/neu状态的免疫组织化学与荧光原位杂交评估比较

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.

作者信息

Kuo Shou-Jen, Wang Boris Bao-Tyan, Chang Cheng-Shyong, Chen Tze-Ho, Yeh Kun-Tu, Lee Dong-Jay, Yin Pao-Lun, Chen Ming

机构信息

Department of Medical Research, Changhua Christian Hospital, Changhua, Taiwan.

出版信息

Taiwan J Obstet Gynecol. 2007 Jun;46(2):146-51. doi: 10.1016/S1028-4559(07)60008-4.

Abstract

OBJECTIVE

Accurate diagnostic assessment of human epidermal growth factor receptor-2 (HER-2) is essential and a prerequisite for appropriate application of the humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin) to the treatment of patients with breast cancer. Immunohistochemistry (IHC) is the most widely applicable diagnostic modality in studying HER-2 status. Fluorescence in situ hybridization (FISH) is also recognized as a modality in cases with an equivocal IHC status (score, 2+). Some authors claimed that FISH alone is sufficient. The aim of this study was to correlate the test results of IHC and FISH for HER-2 gene amplification in breast cancer patients. FISH for topoisomerase IIalpha (TOP2A) was also studied to see if deletion or amplification of TOP2A has any supplementary role to HER-2, FISH and IHC.

MATERIALS AND METHODS

Assessment of HER-2 gene amplification and TOP2A gene amplification/deletion was made by FISH analysis using the LSI TOP2A/HER-2/CEP 17 multicolor probe or the LSI HER-2/CEP dual color probe (Vysis, Downers Grove, IL, USA) in formalin-fixed and paraffin-embedded tissue sections of 54 breast cancer patients who were grouped into stages 1+, 2+ or 3+ based on IHC (HercepTest; DakoCytomation, Carpinteria, CA, USA) observations.

RESULTS

None of IHC 1+ breast tumors was HER-2 FISH positive, but three of 18 (17%) IHC 3+ tumors were HER-2 FISH negative. Overall, 53% of the IHC 2+ and 83% of the IHC 3+ cases were HER-2 FISH positive. Only one case with IHC 3+ tumor that was HER-2 FISH positive was found to have TOP2A amplification (>2.0) and no IHC 2+ cases were found to have TOP2A amplification. There were no cases with TOP2A deletion (<0.8) in our whole series. There were also no cases of HER-2 FISH negative tumors, but IHC scored as 2+ or 3+ (0 of 10), to be found with TOP2A amplification. The discordance rates by IHC were high (46.7% in IHC 2+, 16.7% in IHC 3+, 30.3% overall in IHC 2+ or 3+). On the contrary, the discordance rates were zero if by FISH.

CONCLUSION

The current algorithm to use HER-2 FISH as a supplementary role to IHC HercepTest 2+ may need some modifications according to the local setting. TOP2A FISH adds little value to HER-2 FISH and IHC staining in our study.

摘要

目的

准确诊断评估人表皮生长因子受体2(HER-2)至关重要,是将人源化抗HER-2单克隆抗体曲妥珠单抗(赫赛汀)合理应用于乳腺癌患者治疗的前提条件。免疫组织化学(IHC)是研究HER-2状态时应用最广泛的诊断方法。荧光原位杂交(FISH)在免疫组织化学状态不明确(评分为2+)的病例中也被视为一种诊断方法。一些作者声称仅FISH就足够了。本研究的目的是将乳腺癌患者HER-2基因扩增的免疫组织化学和FISH检测结果进行对比。还对拓扑异构酶IIα(TOP2A)进行FISH研究,以观察TOP2A的缺失或扩增对HER-2、FISH和免疫组织化学是否有任何补充作用。

材料与方法

使用LSI TOP2A/HER-2/CEP 17多色探针或LSI HER-2/CEP双色探针(美国伊利诺伊州唐纳斯格罗夫市Vysis公司),通过FISH分析对54例乳腺癌患者福尔马林固定、石蜡包埋的组织切片进行HER-2基因扩增和TOP2A基因扩增/缺失评估,这些患者根据免疫组织化学(HercepTest;美国加利福尼亚州卡平特里亚市达科细胞公司)观察结果分为1+、2+或3+期。

结果

免疫组织化学1+的乳腺肿瘤中无一例HER-2 FISH呈阳性,但18例免疫组织化学3+肿瘤中有3例(17%)HER-2 FISH呈阴性。总体而言,免疫组织化学2+病例中有53%、免疫组织化学3+病例中有83%的HER-2 FISH呈阳性。仅发现1例免疫组织化学3+肿瘤且HER-2 FISH呈阳性的病例存在TOP2A扩增(>2.0),未发现免疫组织化学2+病例存在TOP2A扩增。在我们的整个系列中,没有TOP2A缺失(<0.8)的病例。也没有发现HER-2 FISH阴性但免疫组织化学评分为2+或3+(10例中0例)的肿瘤存在TOP2A扩增。免疫组织化学的不一致率较高(免疫组织化学2+中为46.7%,免疫组织化学3+中为16.7%,免疫组织化学2+或3+总体为30.3%)。相反,若依据FISH,不一致率为零。

结论

当前将HER-2 FISH作为免疫组织化学HercepTest 2+的补充方法的算法可能需要根据当地情况进行一些修改。在我们的研究中,TOP2A FISH对HER-2 FISH和免疫组织化学染色几乎没有增加价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验